In addition to being the strongest determinant for the presence of MASLD compared to healthy controls, PNPLA3 rs738409[G] also conferred the highest risk of steatosis severity and modified the presence of portal fibrosis. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.